These findings are consistent with those of previous studies that reported the antitumor effects of MDM2 inhibitors, including nutlin-3 in osteosarcoma [45], nutlin-3a in leukemia and neuroblastoma [46,47], and HDM201 in melanoma and liver adenocarcinoma [18,48]. Here, MDM2 is linked to osteosarcoma.